| Abstrakt: |
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced the appointment of Hagop Youssoufian, M.Sc., M.D., as Chief Medical Officer. In this position, Dr. Youssoufian will be responsible for overseeing the clinical development and operations of BIND’s internal pipeline. Edward Schnipper, M.D., who has been serving as interim CMO since January 2014, will continue in an advisory role. [ABSTRACT FROM PUBLISHER] |
